The concept of treatment-free remission in chronic myeloid leukemia

Por Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X
Publicado no Leukemia (2016)

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

Por Airiau, K, Mahon, F-X, Josselin, M, Jeanneteau, M, Belloc, F
Publicado em 2013

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells

Por Joha, S, Nugues, A-L, Hétuin, D, Berthon, C, Dezitter, X, Dauphin, V, Mahon, F-X, Roche-Lestienne, C, Preudhomme, C, Quesnel, B, Idziorek, T
Publicado em 2012

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence

Por Drullion, C, Trégoat, C, Lagarde, V, Tan, S, Gioia, R, Priault, M, Djavaheri-Mergny, M, Brisson, A, Auberger, P, Mahon, F-X, Pasquet, J-M
Publicado em 2012

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Por le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Publicado no Leukemia (2016)

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

Por Seymour, J F, Kim, D W, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, J L, Mahon, F-X, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A, Giles, F J
Publicado no Blood Cancer J (2014)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Por Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Publicado no Leukemia (2017)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Por Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Publicado no Leukemia (2016)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Por Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, A, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S
Publicado no Leukemia (2017)

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Por Cross, N C P, White, H E, Ernst, T, Welden, L, Dietz, C, Saglio, G, Mahon, F-X, Wong, C C, Zheng, D, Wong, S, Wang, S-S, Akiki, S, Albano, F, Andrikovics, H, Anwar, J, Balatzenko, G, Bendit, I, Beveridge, J, Boeckx, N, Cerveira, N, Cheng, S-M, Colomer, D, Czurda, S, Daraio, F, Dulucq, S, Eggen, L, El Housni, H, Gerrard, G, Gniot, M, Izzo, B, Jacquin, D, Janssen, J J W M, Jeromin, S, Jurcek, T, Kim, D-W, Machova-Polakova, K, Martinez-Lopez, J, McBean, M, Mesanovic, S, Mitterbauer-Hohendanner, G, Mobtaker, H, Mozziconacci, M-J, Pajič, T, Pallisgaard, N, Panagiotidis, P, Press, R D, Qin, Y-Z, Radich, J, Sacha, T, Touloumenidou, T, Waits, P, Wilkinson, E, Zadro, R, Müller, M C, Hochhaus, A, Branford, S
Publicado no Leukemia (2016)